Literature DB >> 8537133

Antimicrobial agents for community-acquired respiratory tract infections.

A L Barry1.   

Abstract

Chemotherapy of community-acquired respiratory tract infections was reviewed from a microbiological perspective. The current worldwide spread of penicillin-resistant Streptococcus pneumoniae and of ampicillin-resistant Haemophilus influenzae has required a reassessment of the antimicrobial agents being used for empiric therapy. In vitro data with different orally administered antibiotics were reviewed in order to identify any deficiencies in their spectra of activity against four common respiratory tract pathogens. Cefixime, cefuroxime axetil, cefprozil, amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole were active against all four species other than penicillin-resistant pneumococci.

Entities:  

Mesh:

Year:  1995        PMID: 8537133     DOI: 10.1007/bf01742985

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  24 in total

1.  A national collaborative study of resistance to antimicrobial agents in Haemophilus influenzae in Australian hospitals. The Australian Group for Antimicrobial Resistance (AGAR).

Authors:  P J Collignon; J M Bell; S J MacInnes; G L Gilbert; M Toohey
Journal:  J Antimicrob Chemother       Date:  1992-08       Impact factor: 5.790

2.  Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics.

Authors:  J Liñares; T Alonso; J L Pérez; J Ayats; M A Domínguez; R Pallarés; R Martín
Journal:  J Antimicrob Chemother       Date:  1992-09       Impact factor: 5.790

3.  The Second European Collaborative Study on the frequency of antimicrobial resistance in Haemophilus influenzae.

Authors:  F H Kayser; G Morenzoni; P Santanam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

Review 4.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

5.  Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

Authors:  J Liñares; R Pallares; T Alonso; J L Perez; J Ayats; F Gudiol; P F Viladrich; R Martin
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

6.  Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis isolated in the UK from sputa.

Authors:  M Powell; D McVey; M H Kassim; H Y Chen; J D Williams
Journal:  J Antimicrob Chemother       Date:  1991-08       Impact factor: 5.790

Review 7.  Haemophilus influenzae: antibiotic susceptibility.

Authors:  C A Needham
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

8.  High rates of erythromycin-resistant Streptococcus pneumoniae among penicillin-resistant strains.

Authors:  F Soriano; R Fernández-Roblas
Journal:  J Antimicrob Chemother       Date:  1993-03       Impact factor: 5.790

Review 9.  Genetics and molecular biology of beta-lactam-resistant pneumococci.

Authors:  T J Coffey; C G Dowson; M Daniels; B G Spratt
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

10.  Nasopharyngeal carriage of antibiotic-resistant pneumococci by children in group day care.

Authors:  F W Henderson; P H Gilligan; K Wait; D A Goff
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

View more
  2 in total

1.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Fungal diseases of the respiratory tract.

Authors:  E Dorko; E Pilipcinec; L Tkáciková
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.